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Introduction {#sec004}
============

Scrub typhus is a neglected tropical disease caused by the obligate intracellular bacterium *Orientia tsutsugamushi* \[[@pntd.0007158.ref001]\]. Transmission of the bacteria to humans occurs via the bite of larval trombiculid mites, known commonly as chiggers \[[@pntd.0007158.ref002]\]. It was formerly thought to be confined to the 'tsutsugamushi triangle', encompassing Pakistan, Northern Australia and parts of Russia. However, cases acquired in Chile \[[@pntd.0007158.ref003], [@pntd.0007158.ref004]\], possibly Africa \[[@pntd.0007158.ref005], [@pntd.0007158.ref006]\], as well as the Middle East \[[@pntd.0007158.ref007]\] (by a proposed novel species *O*. *chuto*), have been reported, suggesting that its endemicity may be more widespread than previously thought.

Patients typically present with acute febrile illness, but if left untreated, this may progress to systemic infection and multi-organ failure, contributing to an estimated median mortality rate of 6.0% for untreated and 1.4% for treated scrub typhus \[[@pntd.0007158.ref008]\] highlighting the importance of early and accurate diagnosis. A characteristic necrotic lesion, or eschar, at the inoculation site may serve as a diagnostic clue, however its presence varies, ranging from 9%-97% depending on the population \[[@pntd.0007158.ref009], [@pntd.0007158.ref010]\]. Given that other febrile illnesses such as typhoid, dengue and leptospirosis have similar clinical manifestations as scrub typhus, laboratory test is essential to differentiate scrub typhus from other undifferentiated fever \[[@pntd.0007158.ref011]\].

Serological methods are more often used to diagnose scrub typhus due to their simplicity and cost-effectiveness \[[@pntd.0007158.ref012]\]. The indirect immunofluorescence assay (IFA) is considered the "gold standard," but the requirement of a fluorescent microscope and the subjective nature of reading slides limits its application in rural areas where this disease is most prevalent \[[@pntd.0007158.ref008], [@pntd.0007158.ref011]--[@pntd.0007158.ref014]\]. The Weil-Felix test is convenient to perform but suffers from poor sensitivity and specificity \[[@pntd.0007158.ref013], [@pntd.0007158.ref014]\]. Given the limitations of other serological methods, the enzyme-linked immunosorbent assay (ELISA) is acknowledged as a reasonably simple to perform alternative, providing an objective optical density (OD) result using an automated plate reader, that is reproducible in most clinical laboratory settings \[[@pntd.0007158.ref013]\].

Despite the apparently standardized and objective ELISA platform, the diagnostic accuracy is influenced by methodological and patient factors. Methodological factors may include the composition of antigenic strains and their origin, and the choice of diagnostic cut-off. Patient factors are mainly centered on elevated levels of background immunity in endemic areas that may give rise to false positive results. Therefore, to ensure accuracy of diagnosis, standardized methodologies and locally validated OD cut-off levels for ELISA are urgently needed \[[@pntd.0007158.ref008]\].

This review therefore aims to summarize (1) the differences in ELISA methodologies, (2) the OD cut-offs used for diagnosing scrub typhus in research, and (3) the rationale behind the selection of certain OD cut-offs for scrub typhus diagnosis in previously published diagnostic accuracy studies and observational studies.

Materials and methods {#sec005}
=====================

Search strategy and eligibility criteria {#sec006}
----------------------------------------

A scoping review was performed. Searches were performed by one author (MP) on the PubMed electronic database using the following search terms: "scrub typhus," "tsutsugamushi", "immunoassay", and "ELISA". The search was restricted to papers published in English, up to 16^th^ October 2017. The titles and abstracts were screened for relevance. The full-text of relevant articles were assessed to determine eligibility. Diagnostic accuracy and observational studies using ELISA to diagnose scrub typhus in human were included. We excluded co-infection studies, case studies and studies investigating variations of the conventional ELISA methods (e.g., dot-ELISA). Reference lists of the relevant articles were also screened in order to identify additional studies. The protocol of this review was registered in the International Prospective Register for Systematic Review (PROSPERO) with registration number CRD42017078596.

Data extraction and analysis {#sec007}
----------------------------

Data was extracted by one author (MP), and where the information was unclear a second researcher was consulted (SDB). Details of the sample size, location, study date, reference test, cut-off, method used to calculate the cut-off, and ELISA methodology (antigenic strain and antibody isotype) were compiled into summary tables. The studies were grouped according to study design (diagnostic accuracy study or observational study), type of ELISA (in-house or commercial), and study location. The data was summarized using narrative synthesis. We did not evaluate minutiae of individual ELISA protocols, but instead focusing on the wider issues such as the methodologies used to determined diagnostic cut-offs.

Results {#sec008}
=======

Summary of studies {#sec009}
------------------

### Study types {#sec010}

Of the total of 46 studies included in this review ([Fig 1](#pntd.0007158.g001){ref-type="fig"}), 24 (52.2%, 24/46) were observational studies and the remaining 22 (47.8%, 22/46) were diagnostic accuracy studies (Tables [1](#pntd.0007158.t001){ref-type="table"}--[3](#pntd.0007158.t003){ref-type="table"}). Eighteen (81.8%, 18/22) of the diagnostic accuracy study tested the accuracy of ELISA against reference assays, while the remaining four (18.2%, 4/22) used ELISA as the reference assay.

![The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.](pntd.0007158.g001){#pntd.0007158.g001}
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###### Summary of ELISA diagnostic accuracy studies.

![](pntd.0007158.t001){#pntd.0007158.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Location                                      Year                                                                               Status                Antigen                                                                          Cut-off selection rationale                                   Isotype                 Cut-off (OD)[^a^](#t001fn001){ref-type="table-fn"}                                                              Reference test                                                                                                                   Sample size                                          Study
  --------------------------------------------- ---------------------------------------------------------------------------------- --------------------- -------------------------------------------------------------------------------- ------------------------------------------------------------- ----------------------- --------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- --------------------------------------------------
  Australia, Thailand                           Not stated                                                                         In house              Karp and Gilliam\                                                                ROC analysis\                                                 IgM                     Native Karp---0.4\                                                                                              IIP IgG titre ≥1:1,600, IgM ≥1:400                                                                                               148                                                  Land et al, 2000 \[[@pntd.0007158.ref018]\]
                                                                                                                                                         r56-kDa Karp                                                                     Selected arbitrarily (for IgM and IgG in-combination ELISA)                           Native Gilliam---0.2\                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                r56 Karp---unclear\                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                In combination---0.45                                                                                                                                                                                                                                                                                 

  IgG                                           r56 Karp---0.5\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                In combination---0.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  US soldiers (prior to deployment), Thailand   1986\                                                                              In-house\             Karp, Kato and Gilliam                                                           Mean OD + 2SD\                                                IgM                     US\                                                                                                             IIP IgG titre \>1:1,600, IgM \>1:400                                                                                             373                                                  Suwanabun et al, 1997 \[[@pntd.0007158.ref019]\]
                                                1991--1992                                                                         (NMRC)                                                                                                 ROC analysis                                                                          Mean OD + 2SD---0.28                                                                                                                                                                                                                                                                                  

  IgG                                           US\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                Mean OD +2SD---0.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Thai\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Mean OD +2SD---0.42\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  ROC curve---0.8--1.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Thailand                                      1994--1995                                                                         In-house\             Truncated r56-kDa Karp (from New Guinea)                                         Mean OD + 2SD                                                 IgM                     0.064 (1:400)                                                                                                   IIP with different cut-off titres                                                                                                202                                                  Ching et al, 1998 \[[@pntd.0007158.ref022]\]
                                                                                                                                   (NMRC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  IgG                                           0.11 (1:400)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                1991--1992\                                                                        In-house (NMRC)       Karp, Kato and Gilliam\                                                          Mean OD + 2SD                                                 IgM, IgG                Not stated                                                                                                      IIP IgG titre \>1:1,600, IgM \>1:400                                                                                             430                                                  Coleman et al, 2002 \[[@pntd.0007158.ref031]\]
                                                1993--1999                                                                                               r56-kDa Karp                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                2006--2007                                                                         Commercial (InBios)   r56-kDa                                                                          Mean OD + 3SD\                                                IgM                     0.6                                                                                                             IFA \>1:400                                                                                                                      152                                                  Blacksell et al, 2015 \[[@pntd.0007158.ref012]\]
                                                                                                                                                                                                                                          ROC analysis                                                                                                                                                                                                                                                                                                                                                                                

  0.5                                           IFA\>1:1,600                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  0.4--0.5                                      IFA 4-fold rise                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  0.4--0.5                                      IFA admission sample ≥ 1:3,200 or 4-fold rise to ≥1:3,200 in convalescent sample                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  0.4--0.5                                      Isolation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  0.4                                           PCR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  0.2--0.3                                      STIC (isolation, IFA admission ≥1:12,800, 4-fold rise, 2/3 positive PCR assays)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  0.357                                         STIC (Mean OD + 3SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  0.5                                           Based on all reference modalities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                2007--2008                                                                         In-house\             Karp, Kato and Gilliam                                                           Bayesian LCM                                                  IgM                     1.474 (1:400 dilution)                                                                                          PCR (2/3 assays), eschar, IFA admission titre ≥1:3,200/IFA admission ≥1:3,200 or 4-fold rise to ≥1:3,200 in convalescent-phase   135                                                  Blacksell et al, 2016 \[[@pntd.0007158.ref023]\]
                                                                                                                                   (NMRC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                2010--2013                                                                         In-house\             r56-kDa Karp and TA763, Kato, and Gilliam                                        Mean OD + SD (99% CI)\                                        IgM                     Mean OD + SD---0.320\                                                                                           IgG or IgM ≥400 (IFA) or\                                                                                                        248                                                  Chao et al, 2017 \[[@pntd.0007158.ref024]\]
                                                                                                                                   (NMRC)                                                                                                 ROC analysis                                                                          ROC curve---0.360                                                                                               4-fold increase in IgG or IgM titre (IFA); or\                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                PCR positive                                                                                                                                                                          

  IgG                                           Mean OD + SD---0.816\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                ROC curve---1.305                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  India                                         2011--2012                                                                         Commercial\           r56-kDa                                                                          Not stated                                                    IgM                     0.5                                                                                                             IFA                                                                                                                              1564                                                 Mørch et al, 2017 \[[@pntd.0007158.ref032]\]
                                                                                                                                   (InBios)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  2011--2013                                    Commercial\                                                                        r56-kDa               ROC analysis                                                                     IgM                                                           0.41                    Unclear                                                                                                         145                                                                                                                              Patricia et al, 2017 \[[@pntd.0007158.ref025]\]      
                                                (InBios)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  2012--2013                                    Commercial\                                                                        r56-kDa               Recommendations from InBios kit protocol[^b^](#t001fn002){ref-type="table-fn"}   IgM                                                           1.0                     Micro-IFA---≥1:128                                                                                              546                                                                                                                              Koraluru et al, 2015 \[[@pntd.0007158.ref014]\]      
                                                (InBios)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  2013--2015                                    Commercial\                                                                        r56-kDa               Mean OD + 3SD\                                                                   IgM                                                           Mean OD + 3SD---0.89\   Response to antibiotic treatment within 48hr; and\                                                              298                                                                                                                              Gupta et al, 2016 \[[@pntd.0007158.ref026]\]         
                                                (InBios)                                                                                                 ROC analysis                                                                                                                                   ROC curve---0.87        PCR or eschar                                                                                                                                                                                                                                                                                         

  2013--2015                                    Commercial\                                                                        r56-kDa               Mean OD + 3SD                                                                    IgM                                                           0.89                    IFA \>1:64                                                                                                      256                                                                                                                              Gupta et al, 2017 \[[@pntd.0007158.ref033]\]         
                                                (InBios)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  2012--2013                                    Commercial\                                                                        r56-kDa               Mean OD + 3SD                                                                    IgM, IgG                                                      Not stated              ELISA was used as the reference test                                                                            45                                                                                                                               Stephen et al, 2015 \[[@pntd.0007158.ref034]\]       
                                                (InBios)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  2013--2014                                    Commercial\                                                                        r56-kDa               Mean OD + 3SD                                                                    IgM, IgG                                                      Not stated              IFA IgM ≥ 1:10, IgG ≥ 1:40                                                                                      87                                                                                                                               Kim et al, 2016 \[[@pntd.0007158.ref035]\]           
                                                (InBios)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  2013--2014                                    Commercial\                                                                        r56-kDa               Mean OD + 3SD                                                                    IgM, IgG                                                      Not stated              ELISA was used as the reference test                                                                            127                                                                                                                              Stephen et al, 2016 \[[@pntd.0007158.ref036]\]       
                                                (InBios)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  2015--2016                                    Commercial\                                                                        r56-kDa               Mean OD + 3SD                                                                    IgM                                                           0.56                    ELISA was used as the reference test                                                                            240                                                                                                                              Anitharaj et al, 2016 \[[@pntd.0007158.ref037]\]     
                                                (InBios)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Unclear                                       Commercial (InBios)                                                                r56-kDa               Not stated                                                                       IgM                                                           0.5                     ELISA and eschar presence were used as the reference test                                                       24                                                                                                                               Janardhanan et al, 2014 \[[@pntd.0007158.ref020]\]   

  Korea                                         1988--1991                                                                         In-house              r56-kDa Boryong                                                                  Mean OD + 3SD                                                 IgM                     \~0.1                                                                                                           IFA seroconversion or 4-fold rise                                                                                                170                                                  Kim et al, 1993 \[[@pntd.0007158.ref038]\]

                                                1997                                                                               In-house              r56-kDa Boryong                                                                  Mean OD + 3SD                                                 IgM                     0.2                                                                                                             IFA ≥ 1:80                                                                                                                       176                                                  Jang et al, 2003 \[[@pntd.0007158.ref039]\]

                                                1999--2000                                                                         In-house              Chimeric r56-kDa\                                                                Compared patients and negative controls                       IgM, IgG                0.2                                                                                                             IFA seroconversion or 4-fold rise\                                                                                               Unclear                                              Kim et al, 2013 \[[@pntd.0007158.ref015]\]
                                                                                                                                                         21-kDa Boryong\                                                                                                                                                                                                                                                                        IgM IFA ≥ 1:10\                                                                                                                                                                       
                                                                                                                                                         56-kDa Kangwon 87--61                                                                                                                                                                                                                                                                  IgG IFA ≥ 1:40                                                                                                                                                                        

  Japan                                         2000--2012                                                                         In-house              Kato, Karp, Gilliam, Kuroki, and Kawasaki                                        Mean OD + 2, 3, and 4 SD                                      IgM, IgG                Mean + 3 SD (0.1789 for IgM and 0.2121 for IgG) and/or \>4-fold rise of ELISA antibody titres for paired sera   Micro-IFA \>1:80 and/or ≥4-fold rise for paired samples                                                                          49                                                   Ogawa et al, 2017 \[[@pntd.0007158.ref021]\]

  China                                         Unclear                                                                            In-house              Truncated r56-kDa Ptan                                                           Mean OD + 2SD                                                 IgG\                    0.16 (1:400)\                                                                                                   Unclear                                                                                                                          56                                                   Cao et al, 2007 \[[@pntd.0007158.ref040]\]
                                                                                                                                                                                                                                                                                                        IgM                     0.12 (1:400)                                                                                                                                                                                                                                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ All cut-offs are for a 1:100 dilution, unless stated otherwise

^b^ InBios kits generally recommend a cut-off of the mean OD of non-scrub typhus serum samples + 3SD

10.1371/journal.pntd.0007158.t002

###### Summary of observational studies with a diagnostic accuracy component using InBios ELISAs.

![](pntd.0007158.t002){#pntd.0007158.t002g}

  Location    Sample collection time   Cut-off selection rationale                       Isotype    Cut-off (OD)   Sample size   Study
  ----------- ------------------------ ------------------------------------------------- ---------- -------------- ------------- ---------------------------------------------------
  India       2005--2010               Not stated                                        IgM        0.5            623           Varghese et al, 2014 \[[@pntd.0007158.ref041]\]
              2009--2010               Not stated                                        IgM        1.0            259           Attur et al, 2013 \[[@pntd.0007158.ref042]\]
              2009--2010               Not stated                                        IgM        0.5            154           Varghese et al, 2013 \[[@pntd.0007158.ref043]\]
              2009--2011               Mean OD + 3SD                                     IgM        0.5            191           Astrup et al, 2014 \[[@pntd.0007158.ref044]\]
              2010--2012               Mean OD + 2SD                                     IgM        0.6            167           Kalal et al, 2016 \[[@pntd.0007158.ref045]\]
  IgG         0.37                                                                                                               
              2010--2012               Not stated                                        IgM        0.5            263           Varghese et al, 2015 \[[@pntd.0007158.ref046]\]
              2011--2012               Not stated                                        IgM        0.5            42            Sengupta et al, 2014 \[[@pntd.0007158.ref047]\]
              2012--2013               "As used in other studies"                        IgM        0.5            284           Bhargava et al, 2016 \[[@pntd.0007158.ref048]\]
              2013                     Not stated                                        IgM, IgG   0.5            100           Sengupta et al, 2015 \[[@pntd.0007158.ref027]\]
              2013--2014               Not stated                                        IgM        0.5            239           Sood et al, 2016 \[[@pntd.0007158.ref049]\]
              2013--2014               Mean OD + 3SD                                     IgM        0.5            113           Usha et al, 2015 \[[@pntd.0007158.ref050]\]
              2012--2015               Mean OD + 3SD                                     IgM        0.5            482           Roopa et al, 2015 \[[@pntd.0007158.ref051]\]
              Unclear                  Based on the mean of the 'mixture distribution'   IgM        0.8            721           Trowbridge et al, 2017 \[[@pntd.0007158.ref052]\]
  IgG         1.8                                                                                                                
  China       2012--2014               Not stated                                        IgM        0.3            42            De et al, 2015 \[[@pntd.0007158.ref053]\]
  IgG         0.5                                                                                                                
              2013--2014               Not stated                                        IgM, IgG   0.5            402           Hu et al, 2015 \[[@pntd.0007158.ref028]\]
              2014--2016               Mean OD + 3SD                                     IgM        0.5            135           Chen et al, 2017 \[[@pntd.0007158.ref054]\]
  Malaysia    2007--2010               Mean OD + 3SD                                     IgG        Not stated     300           Tay et al, 2013 \[[@pntd.0007158.ref055]\]
  Sri Lanka   2012--2013               Mean OD + 3SD                                     IgM, IgG   Not stated     64            Pradeepan et al, 2014 \[[@pntd.0007158.ref056]\]
  Nepal       2015                     Based on controls                                 IgM        0.5            434           Upadhyay et al, 2016 \[[@pntd.0007158.ref057]\]

10.1371/journal.pntd.0007158.t003

###### Summary of observational studies using NMRC in-house ELISAs.

![](pntd.0007158.t003){#pntd.0007158.t003g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Location              Sample collection time   Cut-off selection rationale   Antigen                        Isotype   Cut-off (OD)                                                                                       Sample size   Study
  --------------------- ------------------------ ----------------------------- ------------------------------ --------- -------------------------------------------------------------------------------------------------- ------------- -----------------------------------------------
  Korea (US military)   1990--1995               Not stated                    Karp, Kato and Gilliam         IgG       Initial screen-- 0.5 (1:100)\                                                                      9303          Jiang et al, 2015 \[[@pntd.0007158.ref017]\]
                                                                                                                        Second screen---Net total absorbance ≥1.0\                                                                       
                                                                                                                        Active infection---≥ 4-fold increase                                                                             

  Japan (US military)   2000\                    Not stated                    r56-kDa Karp, Kato, Gilliam\   IgG       Titre \>mean + 3SD or the titre that had an absorbance of at least 0.2 (whichever was greater).\   64            Jiang et al, 2003 \[[@pntd.0007158.ref016]\]
                        2001                                                   Karp, Kato, Gilliam\                     Confirmation---convalescent titter of \>100 and a total absorbance \>1                                           
                                                                               r56-kDa Karp ELISA                                                                                                                                        

  Bangladesh            2010                     Citing previous study         Karp and Gilliam               IgM       Net total absorbance ≥0.2 or ≥1.0 if there is no consensus                                         1250          Maude et al, 2014 \[[@pntd.0007158.ref058]\]

  Peru                  2013                     Not stated                    Karp, Kato and Gilliam         IgG       Initial screen-- 0.5 (1:100)\                                                                      1124          Kocher et al, 2017 \[[@pntd.0007158.ref059]\]
                                                                                                                        Second screen---Net total absorbance ≥1.0 (1:100, 1:400, 1:1600, 1:6400)\                                        
                                                                                                                        Active infection---≥ 4-fold increase, and minimum of 1:400 in convalescent sample                                

  India                 2013--2015               Not stated                    Karp, Kato and Gilliam         IgG       Initial screen-- 0.5 (1:100)\                                                                      1265          Khan et al, 2016 \[[@pntd.0007158.ref060]\]
                                                                                                                        Second screen---Net total absorbance ≥1.0\                                                                       
                                                                                                                        Active infection---≥ 4-fold increase                                                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Patient and geographic details {#sec011}

Study year of included articles varying from 1986 to 2016 (Tables [1](#pntd.0007158.t001){ref-type="table"}--[3](#pntd.0007158.t003){ref-type="table"}). The total samples analyzed was 23,498, however one study did not provide the number of samples \[[@pntd.0007158.ref015]\]. Geographically, the majority of the ELISA studies were conducted on serum samples from India (52.2%, 24/46), followed by Thailand (15.2%, 7/46), China (8.7%, 4/46) and Korea (8.7%, 4/46). The remaining study populations were recruited from Japan, the United States (US), Australia, Malaysia, Bangladesh, Sri Lanka, Peru and Nepal (Tables [1](#pntd.0007158.t001){ref-type="table"}--[3](#pntd.0007158.t003){ref-type="table"}). Two studies investigated deployed US soldiers (one in Korea, and one in Japan) \[[@pntd.0007158.ref016], [@pntd.0007158.ref017]\]. Two studies investigated serum samples from two different countries \[[@pntd.0007158.ref018], [@pntd.0007158.ref019]\], and two studies did not specify a location \[[@pntd.0007158.ref020]\].

ELISA methodology {#sec012}
-----------------

### Source {#sec013}

The commercial ELISA kits manufactured by InBios (InBios International Inc., Seattle WA, USA) (referred to as InBios ELISAs) were the most numerous--being used in 30 studies (65.2%, 30/46) with the remainder being in-house assays. Ten studies (21.7%, 10/46) used ELISA methods developed by the US Naval Medical Research Centre (NMRC) (Tables [1](#pntd.0007158.t001){ref-type="table"} and [3](#pntd.0007158.t003){ref-type="table"}).

### Antigenic composition {#sec014}

There was a wide variety of native and recombinant antigens used in the ELISAs examined. The 30 InBios ELISAs identified in the study used a pool of recombinant 56-kDa proteins from Karp, Kato, Gilliam, and TA716 strains (r56-kDa) (Tables [1](#pntd.0007158.t001){ref-type="table"} and [2](#pntd.0007158.t002){ref-type="table"}). Seven studies (15.2%, 7/46) used in-house ELISAs developed by NMRC, that employed whole-cell native antigens from Karp, Kato, Gilliam strains (Tables [1](#pntd.0007158.t001){ref-type="table"} and [3](#pntd.0007158.t003){ref-type="table"}). While one study (2.2%, 1/46) used only Karp and Gilliam strain for its NMRC-developed in-house ELISAs ([Table 3](#pntd.0007158.t003){ref-type="table"}). There were two NMRC studies (4.3%, 2/46) that used recombinant Karp, Kato, Gilliam and TA763 strain or Karp alone antigens and two studies (4.3%, 2/46) with a combination of both whole cell and recombinant antigens. One study (2.2%, 1/46) used whole-cell Karp, Kato, Gilliam, and adding Kuroki and Kawasaki to the pool \[[@pntd.0007158.ref021]\]. One study (2.2%, 1/46) employed combination of chimeric r56-kDa of Karp, Kato, and Gilliam strain, 21-kDa Boryong, and 56-kDa Kangwon 87--61 strain proteins as antigens. Remaining in-house ELISAs used variations of Karp, Kato, Gilliam, Boryong, and Ptan strains antigens (Tables [1](#pntd.0007158.t001){ref-type="table"} and [3](#pntd.0007158.t003){ref-type="table"}).

Diagnostic accuracy studies: Cut-offs used and methodology for selecting cut-offs {#sec015}
---------------------------------------------------------------------------------

### Diagnostic cut-offs {#sec016}

Eighteen studies (81.8%, 18/22) stated diagnostic cut-offs with considerable variation noted between the cut-offs ([Table 1](#pntd.0007158.t001){ref-type="table"}). Diagnostic cut-offs for IgM ranged from 0.064 \[[@pntd.0007158.ref022]\] to 1.474 \[[@pntd.0007158.ref023]\] OD (both 1:400 sample dilution) and IgG cut-offs ranged from 0.11 \[[@pntd.0007158.ref022]\] to 1.305 \[[@pntd.0007158.ref024]\] OD (both 1:100 sample dilution) which were all from Thai studies ([Table 1](#pntd.0007158.t001){ref-type="table"}). Variation was also apparent in cut offs selected for Indian studies, despite the exclusive use of the InBios ELISA where the IgM cut-offs ranged from 0.41 \[[@pntd.0007158.ref025]\] to 1.0 \[[@pntd.0007158.ref014]\] OD ([Table 1](#pntd.0007158.t001){ref-type="table"}).

Ten (43.5%, 10/22) studies investigated both IgG and IgM. Four of them (40.0%, 4/10) determined higher cut-off values for IgG than IgM. In two cases, the same cut-off was applied to both isotypes. For example, Kim *et al* calculated a cut-off of 0.2 OD for both isotypes despite using different reference standard cut-offs ([Table 1](#pntd.0007158.t001){ref-type="table"}) \[[@pntd.0007158.ref015]\].

### Methodology for selecting cut-offs {#sec017}

Using the reference comparator result to derive a diagnostic cut-off, six out of 22 diagnostic studies (27.3%, 6/22) performed Receiver Operator Characteristic (ROC) analysis, and one (4.5%, 1/22) used Bayesian latent class modelling (LCM).

Fifteen (83.3%, 15/18) diagnostic studies that determined ELISAs accuracy used IFA or IIP as the reference test. IFA/micro-IFA were used in 11 studies (61.1%, 1/18), with diagnostic cut-off titers ranging from 1:10 to 1:12,800 for IgM ([Table 1](#pntd.0007158.t001){ref-type="table"}). Five of these studies (45.5%, 5/11) also used a 4-fold rise between paired samples as a seropositivity criteria in addition to a defined cut-off titer. There were four (22.2%, 4/18) studies that used the indirect immunoperoxidase (IIP) assay as reference test. Two studies that assessed ELISA accuracy did not clearly mention the reference assay. Other reference modalities used include PCR, presence of eschar, *in vitro* isolation, and response to antibiotic treatment \[[@pntd.0007158.ref012], [@pntd.0007158.ref023], [@pntd.0007158.ref024], [@pntd.0007158.ref026]\]. In one study (4.5%, 1/22), a combination of the above was used in the form of scrub typhus infection criteria (STIC) composite \[[@pntd.0007158.ref012]\].

The most commonly used method to determine a diagnostic cut-off was the addition of standard deviations (SD) to the mean OD of negative controls (72.7%, 16/22). There were four studies adding 2 SD, nine diagnostic studies adding 3 SD to the mean OD and one study calculated mean OD + 2, 3, and 4 SD ([Table 1](#pntd.0007158.t001){ref-type="table"}).

Variation in derived IgG cut-offs were noted within two studies that had each used both ROC curves and the mean OD to determine a cut-off for the same population \[[@pntd.0007158.ref019], [@pntd.0007158.ref024]\]. IgM cut-offs remained roughly the same when applying different methods (ROC curves and mean OD) in three studies \[[@pntd.0007158.ref012], [@pntd.0007158.ref024], [@pntd.0007158.ref026]\]. The remaining 16 studies either gave unclear information on the method used, unjustified methods to determine seropositivity (four studies), arbitrarily selected cut-offs (one study), or cut-offs from unpublished data (one study).

Observational studies: Cut-offs used and methodology for selecting cut-offs {#sec018}
---------------------------------------------------------------------------

Out of a total of 24 observational studies, seven (29.2%, 7/24) stated the method to determine the diagnostic cut-off and four (16.7%, 4/24) studies were unclear about how they derived the cut-offs stating "as used in other studies" or similar wording (Tables [2](#pntd.0007158.t002){ref-type="table"} and [3](#pntd.0007158.t003){ref-type="table"}). Of the remaining studies, 13 (54.2%, 13/24) provided no clear explanation as to how the cut-off was selected, however 0.5 OD was used for IgM and/or IgG diagnosis for 11 (45.8%, 11/24) of these studies (Tables [2](#pntd.0007158.t002){ref-type="table"} and [3](#pntd.0007158.t003){ref-type="table"}). Of the 19 observational studies using the InBios ELISA, seven (36.8%, 7/19) ([Table 2](#pntd.0007158.t002){ref-type="table"}) obtained local controls to determine a region-specific cut-off using the mean + 2 or 3 SD method. In the case of the NMRC in-house ELISA studies, the majority of studies (80.0%, 4/5) ([Table 3](#pntd.0007158.t003){ref-type="table"}), instead of calculating a single cut-off, patients were diagnosed with scrub typhus if they passed two criteria: 1) IgM OD ≥0.5 at a 1:100 dilution, and 2) a summed total OD of ≥1.0 of 4 sequential 4-fold dilutions. i.e., 1:100, 1:400, 1:1,600, 1:6,400) ([Table 3](#pntd.0007158.t003){ref-type="table"}).

Discussion {#sec019}
==========

The application of appropriate diagnostic cut-offs is important for timely scrub typhus patient management using appropriate antibiotic therapy and to prevent complications leading to significant detrimental effect. This review has determined that there was a significant lack of consensus regarding methodologies, application and diagnostic cut-offs for ELISAs used for the diagnosis of scrub typhus infections. However, the reasons are complex and require further investigation.

Approximately half of the observational studies provided no or insufficient justification for the OD cut-offs, and two studies did not specify the cut-off they used. Although the 0.5 OD cut-off was used commonly in InBios ELISAs studies and used by the Indian Council of Medical Research (ICMR), this is probably an appropriate estimation for certain parts of India with limited application in other geographic locations. This cut-off should be applied only in regions where it has been validated by testing samples from healthy controls to determine the level of background immunity in the normal population. In some cases, it is difficult to select a cut-off as demonstrated by Blacksell *et al*, where optimal OD cut-offs ranged from 0.2--0.6 OD depending on the reference standards used \[[@pntd.0007158.ref012]\]. Several studies used the same cut-off for IgG and IgM, despite the differences in immunity dynamics of the different antibody isotypes--this should be taken into consideration when interpreting results of such tests \[[@pntd.0007158.ref015], [@pntd.0007158.ref024], [@pntd.0007158.ref027], [@pntd.0007158.ref028]\], as generally, upon infection a spike in IgM is seen, followed by increased levels of IgG, which also confers long-term protection.

There was a lack of uniformity of approach regarding the diagnostic accuracy studies to determine appropriate ELISA cut-offs for various geographic locations. The reference methodologies varied from Bayesian LCM using composite scrub typhus infection criteria (STIC), IFA, through to mean + SD in healthy controls. In most cases, there was no clear justification for the reference test cut-offs employed, and it is likely that some of these cut-offs were not appropriate for the location in which they were being used. For example, while an IFA cut-off of 1:400 is often set in Thailand, it has been suggested to have a high false-positivity rate \[[@pntd.0007158.ref029]\]. Subsequently, the diagnostic accuracy of composites such STIC have also been suggested to overestimate scrub typhus positivity compared with index \[[@pntd.0007158.ref030]\]. Bayesian LCM is being increasingly used to determine true diagnostic accuracies, as they do not assume any reference diagnostic test is perfect \[[@pntd.0007158.ref030]\]. A recent study calculated--using this method--an admission IgM IFA cut-off of ≥1:3,200 or at least a 4-fold rise to ≥1: 3,200 in the convalescent-phase sample to provide the highest accuracy \[[@pntd.0007158.ref029]\]. Only one study in this review used Bayesian LCM; combining IFA, PCR, eschar and culture results as reference standards to interpret ELISA results \[[@pntd.0007158.ref023]\]. Given that the reference standards all have different accuracies, using a composite in a Bayesian approach helps to eliminate bias. Other studies used different approaches that may compromise accuracy. For example, in one study, a response to an unnamed antibiotic, along with positivity by either PCR or presence of an eschar, was used as the diagnostic criteria \[[@pntd.0007158.ref026]\]. Generally, doxycycline is prescribed to treat scrub typhus, however since it is a broad-spectrum antibiotic and also used to treat leptospirosis and murine typhus, a response to treatment may not point specifically to scrub typhus as the cause of illness.

A number of factors may have an influence on the diagnostic accuracy of ELISAs including antigenic composition and sample population. Differences in ELISA methodologies were observed where studies used local antigenic strains or incorporated these into pooled Karp, Kato and Gilliam antigens to supposedly increase the accuracy of the test. In general, higher ODs were obtained when using homologous antigens, therefore variation in cut-offs were likely to be seen depending on the antigen being used and the locally circulating strains. In India, the use of the InBios ELISAs (which used Karp, Kato, Gilliam and TA716 strain antigens) was widely implemented, providing a more standardized means of diagnosing scrub typhus. Jiang et al demonstrated a trivalent r56-kDa protein to be superior to both monovalent r56-kDa Karp and whole-cell Karp, Kato and Gillam ELISAs \[[@pntd.0007158.ref016]\]. The antigens used for deployed soldiers or travelers need to be carefully considered, and results need to be interpreted with caution, given their background immunity is likely to differ significantly from those living in endemic areas. Nevertheless, standardized, region-specific antigen preparations should be used in ELISAs, taking into consideration the circulating strains.

Regarding study populations, the use of samples from diseased or normal subjects as well as the geographic origin of the subjects can affect the derived diagnostic cut-off. In one study, serum samples were collected from Australia and Thailand, but it was unclear to which population the cut-off was applied, or whether the cut-off was calculated using results from both the populations despite differences in endemicity \[[@pntd.0007158.ref018]\].

In addition to a lack of ELISA methodology standardization there was also lack of consensus in what is considered as the gold standard reference assay to determine diagnostic cut-offs. The absence of standardized methods and appropriate cut-offs has implications for seroepidemiology and clinical studies, as well as clinical decision making. On one hand, lower cut-off would result in false positives results risking unnecessary treatment and increasing probability of antimicrobial resistance. On the other hand, higher cut-off would result in false negative results risking cases to be missed.

This review has several limitations. First, it only investigated studies published in English, which may limit literature retrieval. Second, only one author performed the article selection and data extraction, however, any unclear data was discussed amongst the authors in order to limit bias. Lastly, the ELISA protocol was not examined as a factor. This needs to be considered when interpreting results, as differences in protocol (e.g. the amount of antigen used in plate coating) can influence the sensitivity and specificity of ELISA tests, that in turn influence the selection of optimal cut-offs. To limit the heterogeneity caused by different ELISA protocol, variations of the conventional ELISA were excluded from the review, and the InBios ELISA studies were grouped together in the analysis.

Further research will need to be conducted to determine local levels of background immunity, as well as to identify circulating strains, in order to make informed decisions for a region-specific, standardized ELISA methodology and cut-off.
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